Conditional Approval Received to Begin Trading
TORONTO, July 12 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX-V: ARI),
today announced that it has received approval to list its common shares on the
Toronto Stock Exchange ("TSX") conditional on receipt of final documentation.
It is expected that ARIUS' common shares will commence trading on the TSX at
the market open on or about July 24, 2006, under the symbol "ARI". In
conjunction with its move to the TSX, ARIUS' common shares will be de-listed
from and cease trading on the TSX Venture Exchange.
"The graduation to the TSX represents the achievement of a key milestone
in ARIUS' corporate strategy and reflects our achievements in recent months,"
said Dr. David S. Young, President and Chief Scientific Officer of ARIUS,
"With our deal flow, significant financing and this graduation, ARIUS is
positioned for growth and the transition to a clinical company."
About ARIUS Research
ARIUS Research Inc. is a biotechnology company dedicated to personalizing
cancer therapy through the discovery and development of novel anticancer
monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
powerful MAbs targeting a variety of cancer indications. This antibody
generation engine has enabled ARIUS to assemble a growing pipeline, which is
used for commercial collaborations and in-house development. ARIUS has ongoing
partnerships with key biotechnology and drug development companies. The
company is listed on the TSX Venture Exchange under the symbol "ARI".
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
